Skip to main content
TipRanks
Go Ultimate75% OFF

Ensysce Biosciences (ENSC) AI Stock Analysis

323 Followers
ENSC

Ensysce Biosciences

(NASDAQ:ENSC)

Select Model
Rating:39Underperform
Price Target:$0.37â–¼(-4.44% Downside)
Action:downgraded
Date:11/13/26

The overall score of 39 reflects a very high-risk, distressed micro-cap biotechnology company. The most significant factor is the dire financial performance, marked by massive losses and unsustainable cash burn that threaten the company's viability. This is compounded by a bearish technical trend and significant corporate event risks, including ongoing Nasdaq delisting hurdles. The recent financing provides a short-term lifeline but does not resolve the fundamental lack of a path to profitability.

Positive Factors
Low LeverageLow current leverage reduces immediate balance-sheet pressure and gives Ensysce more flexibility than a heavily indebted biotech. Asset growth also provides a stronger financial base, although the company still needs to improve returns and reduce reliance on external capital.
Negative Factors
Deep LossesThe very large loss relative to modest revenue shows that Ensysce has not yet achieved commercial scale or operating leverage. Persistently weak margins leave limited evidence of a self-sustaining business model and make future earnings dependent on successful development, partnering, or additional financing.

Ensysce Biosciences (ENSC) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%ENSC-76.21%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$7.47M
Dividend Yield
―
Average Volume (3M)
537.57K
Price to Earnings (P/E)
-0.1
Beta (1Y)
3.28
Revenue Growth
37.91%
EPS Growth
1.72%
Country
US
Employees
9
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ensysce Biosciences Business Overview & Revenue Model

Company Description

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdos...

How the Company Makes Money

Ensysce Biosciences is a clinical-stage company and does not have publicly established, recurring product sales in the way commercial-stage pharmaceutical companies do; as a result, any routine revenue from marketed drugs is not available. The compan...

Ensysce Biosciences Earnings Call Summary

Earnings Call Date:Mar 15, 2024(Q4-2023)|% Change Since:-96.60%|Next Earnings Date:May 12, 2022
Earnings Call SentimentNeutral

The earnings call highlighted significant clinical achievements, including FDA breakthrough designations and successful trial completions, against a backdrop of financial challenges and reduced funding. The company is making progress toward its goals but needs additional funding to maintain momentum.

Positive Updates

Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.

Negative Updates

Limited Cash Reserves
The company ended 2023 with $1.1 million in cash and cash equivalents, highlighting the need for additional funding to initiate Phase III trials.

Company Guidance

During Ensysce Biosciences' Q4 2023 earnings call, the company provided detailed guidance on its advancements and future plans. Ensysce reported significant clinical progress with its next-generation opioid analgesics, focusing on the PF614 and PF614-MPAR products. The company completed five clinical trials for PF614, including a human abuse potential study and an analgesic efficacy study. Ensysce plans to initiate Phase III trials for PF614 in the second half of 2024, following FDA feedback. They also received breakthrough therapy designation for PF614-MPAR, highlighting its potential to prevent opioid overdose. Financially, Ensysce ended 2023 with $1.1 million in cash, supplemented by early 2024 warrant exercises and plans to raise additional funds before starting Phase III trials. The company’s R&D expenses decreased in 2023, totaling $7.6 million, with a focus on optimizing manufacturing and preparing for pivotal clinical trials.

Ensysce Biosciences Financial Statement Overview

Summary

Financial health is critically weak. The company is pre-revenue with a net loss of $91.2M, deeply negative margins, and an operating cash burn of $8.4M. The recent recapitalization provides only a temporary equity buffer, and the business is entirely dependent on external funding with no path to profitability.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue5.23M5.07M0000
Gross Profit1.61M-5.31M0000
EBITDA-90.99M-10.15M-6.70M-10.27M-24.10M-27.85M
Net Income-91.01M-10.18M-7.99M-10.61M-24.17M-29.08M
Balance Sheet
Total Assets30.95M7.45M5.60M2.71M5.89M16.42M
Cash, Cash Equivalents and Short-Term Investments29.67M4.31M3.50M1.12M3.15M12.26M
Total Debt154.87K306.71K301.66K854.70K4.43M17.21M
Total Liabilities3.84M4.57M2.22M3.36M9.91M24.58M
Stockholders Equity27.44M3.21M3.71M-322.86K-3.71M-7.88M
Cash Flow
Free Cash Flow-8.44M-7.93M-7.50M-10.78M-17.89M-8.24M
Operating Cash Flow-8.39M-7.81M-7.50M-10.78M-17.89M-8.24M
Investing Cash Flow11.39M-123.64K004,5000
Financing Cash Flow25.23M8.74M9.88M8.76M8.77M20.31M

Ensysce Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price0.38

Price Trends

50DMA0.44Negative
100DMA0.39Negative
200DMA0.40Negative

Market Momentum

MACD-0.02Negative
RSI42.86Neutral
STOCH70.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENSC, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.44, and below the 200-day MA of 0.40, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.86 is Neutral, neither overbought nor oversold. The STOCH value of 70.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENSC.

Ensysce Biosciences Risk Analysis

Ensysce Biosciences disclosed 49 risk factors in its most recent earnings report. Ensysce Biosciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks
1.Clinical trials of CY200 or CY201 may be delayed, suspended or terminated, including as a result of clinical holds, a failure to obtain or maintain MHRA clinical trial authorization, an MHRA decision to suspend or terminate a clinical trial, or safety findings, and adverse side effects could result in a restrictive label, a risk mitigation program or the denial of regulatory approval.Q3, 2026
2.There is substantial doubt about our ability to continue as a going concern.Q4, 2023

Ensysce Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ENSC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ENSCENSC39Underperform$7.47M-0.07-1232.64%―37.91%1.72%

* Healthcare Sector Average

Performance Comparison

-50%0%50%ENSCSILOALZNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ENSC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ENSCEnsysce Biosciences, Inc.0.38-1.45-79.07%
SILOSilo Pharma Inc1.71-4.21-71.14%
ALZNAlzamend Neuro, Inc.1.13-1.18-51.08%

Ensysce Biosciences Corporate Events

Executive/Board ChangesShareholder Meetings

Ensysce Biosciences Announces CEO Transition and Director Resignation

Neutral
Nov 4, 2026

On October 29, 2026, CEO Lynn Kirkpatrick agreed to relinquish the CEO title and assume COO responsibilities after the December 14, 2026 annual meeting; President James Morrisson was previously set to become CEO. The transition would be delayed if th...

Business Operations and StrategyRegulatory Filings and Compliance

Ensysce Biosciences Updates Series C Preferred Stock Terms

Neutral
Sep 29, 2026

On August 5, 2026, Ensysce Biosciences filed a Certificate of Designation for its Series C Non-Voting Convertible Preferred Stock with Delaware authorities, followed by a Certificate of Correction on August 6, 2026. These actions established key pref...

Delistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance

Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles

Negative
Aug 25, 2026

On May 21, 2026, Ensysce Biosciences disclosed that Nasdaq had warned the company over non-compliance with the $2.5 million stockholders’ equity requirement as of March 31, 2026, triggering a potential delisting process unless a remediation plan was...

Delistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance

Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period

Positive
Aug 24, 2026

On August 5, 2026, Ensysce Biosciences acquired Cy Biopharma, Inc. and entered into a Securities Purchase Agreement to issue 120,260 shares of Series C Preferred Stock for approximately $43 million in financing, structured in two tranches. At the ini...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026